References
- Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine. 2008;26(Suppl 4):D5–9. doi:https://doi.org/10.1016/j.vaccine.2008.05.076.
- Belshe RB RB, Mendelman PM PM, Treanor J, King J, Gruber WC WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338(20):1405–12. doi:https://doi.org/10.1056/NEJM199805143382002.
- Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother. 2000;54(4):210–18. doi:https://doi.org/10.1016/S0753-3322(00)89027-7.
- De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine. 2009;28(1):228–34. doi:https://doi.org/10.1016/j.vaccine.2009.09.092.
- Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357(14):1373–81. doi:https://doi.org/10.1056/NEJMoa070844.
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan;12(1):36–44. doi:https://doi.org/10.1016/S1473-3099(11)70295-X.
- Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses. 2011;5(2):67–75. doi:https://doi.org/10.1111/j.1750-2659.2010.00183.x.
- Even-or O, Joseph A, Itskovitz-Cooper N, Samira S, Rochlin E, Eliyahu H, Goldwaser I, Balasingam S, Mann AJ, Lambkin-Williams R. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine. 2011;29(13):2474–86. doi:https://doi.org/10.1016/j.vaccine.2011.01.009.
- Even-or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev Vaccines. 2013;12(9):1095–108. doi:https://doi.org/10.1586/14760584.2013.825445.
- Even-or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, Spira J, Goldwaser I, Ellis R, Barenholz Y, et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine. 2010;28(39):6527–41. doi:https://doi.org/10.1016/j.vaccine.2010.04.011.
- Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E. A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide lipid—ceramide carbamoyl-spermine (CCS)I. Immunogenicity and efficacy studies in mice. Vaccine. 2006;24(18):3990–4006. doi:https://doi.org/10.1016/j.vaccine.2005.12.017.
- Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503. doi:https://doi.org/10.1016/j.immuni.2010.10.002.
- Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol. 2002;169(9):4697–701. doi:https://doi.org/10.4049/jimmunol.169.9.4697.
- Metcalf TU, Cubas RA, Ghneim K, Cartwright MJ, Grevenynghe JV, Richner JM, Olagnier DP, Wilkinson PA, Cameron MJ, Park BS. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell. 2015;14(3):421–32. doi:https://doi.org/10.1111/acel.12320.
- Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol. 2006;24(1):353–89. doi:https://doi.org/10.1146/annurev.immunol.24.021605.090552.
- Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 1999;11(4):443–51. doi:https://doi.org/10.1016/S1074-7613(00)80119-3.
- Cohen P. The TLR and IL-1 signalling network at a glance. J Cell Sci. 2014;127(11):2383–90. doi:https://doi.org/10.1242/jcs.149831.
- Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005 2004;17(1):1–14. doi:https://doi.org/10.1093/intimm/dxh186.
- Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol. 2003;69(4):560–67. doi:https://doi.org/10.1002/jmv.10345.
- Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M, Kedar E. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase hemagglutinin–neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 2001;20(3–4):505–15. doi:https://doi.org/10.1016/S0264-410X(01)00326-7.
- de Bruyn G. Cofactors that may influence vaccine responses. Curr Opin HIV AIDS. 2010;5(5):404–08. doi:https://doi.org/10.1097/COH.0b013e32833d1fca.
- Haralambieva IH, Kennedy RB, Ovsyannikova IG, Whitaker JA, Poland GA. Variability in humoral immunity to measles vaccine: new developments. Trends Mol Med. 2015;21(12):789–801. doi:https://doi.org/10.1016/j.molmed.2015.10.005.
- Kraal G, Weissman IL, Butcher EC. Genetic control of T-cell subset representation in inbred mice. Immunogenetics. 1983;18(6):585–92. doi:https://doi.org/10.1007/BF00345966.
- Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995;1(12):1279–83. doi:https://doi.org/10.1038/nm1295-1279.
- Hsieh CS, Macatonia SE, O’Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro.. J Exp Med. 1995;181(2):713–21. doi:https://doi.org/10.1084/jem.181.2.713.
- Jovicic N, Jeftic I, Jovanovic I, Radosavljevic G, Arsenijevic N, Lukic ML, Pejnovic N. Differential Immunometabolic phenotype in Th1 and Th2 dominant mouse strains in response to high-fat feeding. PLoS One. 2015;10(7):e0134089. doi:https://doi.org/10.1371/journal.pone.0134089.
- Daugelat S, Ladel CH, Kaufmann SH. Influence of mouse strain and vaccine viability on T-cell responses induced by mycobacterium bovis bacillus calmette-guerincalmette-guérin. Infect Immun. 1995;63(5):2033–40. doi:https://doi.org/10.1128/IAI.63.5.2033-2040.1995.
- Fujita Y, Taguchi H. Overview and outlook of Toll-like receptor ligand-antigen ligand–antigen conjugate vaccines. Ther Deliv. 2012;3(6):749–60. doi:https://doi.org/10.4155/tde.12.52.
- Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11(1):115–22. doi:https://doi.org/10.1016/S1074-7613(00)80086-2.
- Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season. 2015.
- Ridenhour BJ, Campitelli MA, Kwong JC, Rosella LC, Armstrong BG, Mangtani P, Calzavara AJ, Shay DK. Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged >/= ≥65 years: estimates with generalized linear models accounting for healthy vaccinee effects. PLoS One. 2013;8(10):e76318. doi:https://doi.org/10.1371/journal.pone.0076318.
- Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876. doi:https://doi.org/10.1002/14651858.CD004876.
- DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–45. doi:https://doi.org/10.1056/NEJMoa1315727.
- Richardson DM, Medvedeva EL, Roberts CB, Linkin DR. Centers for disease C, prevention epicenter P. comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015;61(2):171–76. doi:https://doi.org/10.1093/cid/civ261.
- Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, Franks R, Pratt D, Forshee RA, MaCurdy T, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300. doi:https://doi.org/10.1016/S1473-3099(14)71087-4.
- Whitaker JA, von Itzstein MS, Poland GA. Strategies to maximize influenza vaccine impact in older adults. Vaccine. 2018;36(40):5940–48. doi:https://doi.org/10.1016/j.vaccine.2018.08.040.
- Food and Drug Administration. FDA approves first seasonal influenza vaccine containing an adjuvant. Hum Vaccin Immunother. 2018; 14(2):386–95. Published online 2018 Jan 3. doi:https://doi.org/10.1080/21645515.2017.1373227.
- Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccin Immunother. 2018;14(3):550–64. doi:https://doi.org/10.1080/21645515.2017.1415684.
- Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine. 2011;29(17):3341–55. doi:https://doi.org/10.1016/j.vaccine.2010.08.002.
- Goff PH, Hayashi T, He W, Yao S, Cottam HB, Tan GS, Crain B, Krammer F, Messer K, Pu M, et al. Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice. J Virol. 2017;91(19):e01050–17.
- Quintilio W, de Freitas FA, Rodriguez D, Kubrusly FS, Yourtov D, Miyaki C, de Cerqueira Leite LC, Raw I. Vitamins as influenza vaccine adjuvant components. Arch Virol. 2016;161(10):2787–95. doi:https://doi.org/10.1007/s00705-016-2994-5.
- Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D’Oro U, Giuliani MM. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A. 2011;108(27):11169–74. doi:https://doi.org/10.1073/pnas.1107941108.
- O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - – an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341–48. doi:https://doi.org/10.1016/j.vaccine.2011.09.061.
- van den Biggelaar AH, Huizinga TW, de Craen AJ, Gussekloo J, Heijmans BT, Frolich M, Westendorp RGJ. Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Exp Gerontol. 2004;39(9):1407–14. doi:https://doi.org/10.1016/j.exger.2004.06.009.
- Toapanta FR, Ross TM. Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res. 2009;10(1):112. doi:https://doi.org/10.1186/1465-9921-10-112.
- Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging. 2011;28(2):93–106. doi:https://doi.org/10.2165/11586770-000000000-00000.
- Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing. 2007;4(1):9. doi:https://doi.org/10.1186/1742-4933-4-9.
- Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14(5):315–28. doi:https://doi.org/10.1038/nri3665.
- Chen L, Lei L, Chang X, Li Z, Lu C, Zhang X, Wu Y, Yeh I-T, Zhong G. Mice deficient in MyD88 develop a Th2-dominant response and severe pathology in the upper genital tract following chlamydia muridarum infection. J Immunol. 2010;184(5):2602–10. doi:https://doi.org/10.4049/jimmunol.0901593.
- Cohen SJ, Cohen IR, Nussbaum G. IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(-/-) Mice. J Immunol. 2010;184(1):212–21. doi:https://doi.org/10.4049/jimmunol.0900296.
- Dishon S, Cohen SJ, Cohen IR, Nussbaum G. Inhibition of myeloid differentiation factor 88 reduces human and mouse T-Cell Interleukin-17 and IFNγ production and ameliorates experimental autoimmune encephalomyelitis induced in mice. Front Immunol. 2017;8:615. doi:https://doi.org/10.3389/fimmu.2017.00615.
- He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477–88. doi:https://doi.org/10.1080/21645515.2014.1004026.
- Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol. 2008;181(1):17–21. doi:https://doi.org/10.4049/jimmunol.181.1.17.